Par Drugs And Chemicals per share figures

·UnclassifiedChart ›
Share price at each year-end
Tap a line for its trendCurrentlast 12MFY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023FY22 and earlierAlpha Plus
₹10.56₹10.65₹10.86₹11.78₹9.21
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
₹10.56₹10.65₹10.86₹11.78₹9.21
₹91.01₹91.01₹80.44₹69.59₹57.90
₹87.50₹84.24₹82.06₹77.73₹77.82
—₹13.35₹13.13₹16.46₹10.87
₹11.76₹11.76₹12.12₹11.51₹4.67
1.21.21.21.21.2
Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

PAR₹120.70

Par Drugs And Chemicals Limited

· Unclassified
₹ CrorePeersBALAXICROWNSTEELCITYHINDCONLATTEYSHECPROJECTAIROLAMGROBTEAMcap ₹149 Cr
HighlightsEnterprise ValueMultiplesPer ShareAnnuals · FY-end closes
₹ per share
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Current/LTM
TTM · last close
Basic EPS9.2111.7810.8610.6510.56
Diluted EPS9.2111.7810.8610.6510.56
Book Value per Share57.9069.5980.4491.0191.01
Revenue per Share77.8277.7382.0684.2487.50
Cash Flow per Share10.8716.4613.1313.35—
Free Cash Flow per Share4.6711.5112.1211.7611.76
Shares Outstanding (cr)1.21.21.21.21.2
Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · StandaloneFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.